Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing and commercializing therapies for significant unmet medical needs, with an initial emphasis on kidney disease. The company’s business model is to in-license drug technologies, advance them through development and regulatory review, and then commercialize or partner the assets in global markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment and regulatory advancement of OLC and related kidney-disease therapies.
In-licensed technologies and drug candidates acquired for further development.
Potential revenue from partnering, licensing, and related agreements.
Customers
Unicycive’s direct customers are not traditional end-market buyers today; its current economic counterparties are regulators, development partners, licensors, and future pharmaceutical commercialization partners. If approved, its therapies would be used by physicians and patients in kidney disease settings, with commercialization likely supported through partners outside the U.S.
The FDA and other agencies review clinical, manufacturing, and safety data for approval.
Potential licensees or collaborators for ex-U.S. commercialization and development support.
Physicians who would prescribe approved kidney-disease therapies.
Patients who would ultimately receive the company’s approved treatments.
Strategy
The company’s strategy is to advance in-licensed assets through a streamlined development platform, with kidney disease as the initial therapeutic focus. It aims to secure U.S. approval first, then use partnerships to extend commercialization globally while continuing to identify additional disease areas over time.
Regulatory clearance is the key step to convert the lead asset into a commercial product.
Partnerships can extend reach without building a large international sales force.
A broader pipeline reduces dependence on a single asset and therapeutic area.
Geography
Unicycive is headquartered in the United States and focuses first on U.S. regulatory approval for its product candidates. The company also intends to partner with global biopharmaceutical companies for commercialization outside the U.S., so its long-term exposure is tied to both domestic approval pathways and international partnering.
Risks
Unicycive faces the typical risks of a clinical-stage biotech company: regulatory setbacks, manufacturing compliance issues, and uncertainty around whether development assets will reach approval and commercialization. Because the business depends on a small number of programs and external partners, delays or failures in one asset can have an outsized impact on value creation.
The lead program depends on resolving regulatory deficiencies and obtaining approval.
Exposure: Oxylanthanum Carbonate (OLC)
The CRL cited a compliance issue at a third-party manufacturer, showing reliance on external CMC execution.
Exposure: Manufacturing and supply chain
Clinical-stage development typically requires repeated capital raises before product revenue is established.
Exposure: Equity financing and preferred stock structures
The company has a limited number of programs, so setbacks are not easily offset.
Exposure: Single-asset and early pipeline concentration
Accounting
Judgemental itemsLicensing or collaboration revenue depends on performance obligations and timing of control transfer.
Impact: Can shift revenue between periods and affect comparability.
The company records changes in warrant value in other income/expense.
Impact: Can create earnings volatility unrelated to operations.
Contingently redeemable preferred stock is initially recorded outside permanent equity.
Impact: Affects balance sheet presentation and equity analysis.
Clinical and regulatory costs are expensed as incurred rather than capitalized.
Impact: Early-stage development spending drives reported losses and cash burn.
Similar listed companies
Publicly listed companies with a comparable business focus.
Ultragenyx Pharmaceutical Inc.
RARE · Pharmaceutical Preparations
Theriva Biologics, Inc.
TOVX · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
uniQure N.V.
QURE · Pharmaceutical Preparations
Exicure, Inc
XCUR · Pharmaceutical Preparations
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Last updated: 24/09/2026